分子診斷合作與授權協議（2016-2026）

分子診斷領域交易的權威基準

分子診斷領域的合作是由先進的基因組分析和基於生物標記的檢測技術所推動的，其合約結構反映了精準診斷在臨床決策和治療方法開發中日益擴大的作用。

本報告對分子診斷領域的 830 多項合作與許可協議進行了全面系統的分析，清楚地展示了整個市場夥伴關係的設計、談判和執行方式，並以證據為基礎進行了闡述。

清楚了解市場標準

本報告對分子診斷領域的合約實際構成方式進行了精確闡述。

• 類似交易的可靠基準
• 對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析
• 定義切合實際的市場參數
• 清楚洞察基於技術平台、測試應用程式和合作夥伴概況的合約條款差異。
• 支持基於證據的評估和合約結構確定。
• 讓內部討論基於實際交易數據，而不是僅基於假設。
• 了解主要公司的交易方式
• 在精準醫療主導和臨床整合的環境中，可視化合作夥伴的行為模式和重複的合約結構。
• 完全透明地了解合約的結構和執行情況
• 本報告超越了表面的合約數據，提供了對底層合約文件的訪問，以便詳細了解實際協議是如何構建的。

這包括以下內容：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和付款條款
• 關鍵合約條款和保護措施
• 這種透明度對於理解分子診斷領域合作中價值、風險和控制權的分配至關重要。在監管要求、臨床效用和檢測準確性是關鍵考慮的領域，其重要性更為突出。
• 專為實際業務發展和策略應用而設計。

本報告廣泛用於以下用途：

• 建構和評估與診斷和精準醫療相關的交易。
• 在清晰的市場環境下準備談判
• 評估技術合作夥伴和合作機會
• 利用可靠且可解釋的數據支持內部策略規劃

本報告內容：

• 超過 830 項與分子診斷相關的合作和許可協議。
• 財務條款，包括預付款、里程碑付款和特許權使用費（如已揭露）。
• 可全文搜尋的合約目錄（按公司、技術和應用）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 合約趨勢、重大交易和活躍合約方分析。
• 可靠的、依證的分子診斷交易參考材料
• 本報告結合了全面的合約資料覆蓋和詳細的合約層面分析，為在分子診斷領域建立、談判和評估夥伴關係提供了可靠的、依證的資源。

目錄

執行摘要

第1章：引言

第2章：分子診斷領域的交易趨勢

• 過去幾年分子診斷領域的合作
• 分子診斷產業中最活躍的參與者
• 分子診斷合約：按合約類型分類
• 分子診斷合約：按治療領域分類
• 分子診斷合約：按行業分類
• 分子診斷合約條款
  • 標題金額
  • 預付款
  • 里程碑付款
  • 權利金費率

第3章 主要分子診斷合約

• 按合約價值排名的前幾大分子診斷合約

第4章：分子診斷這一最活躍領域的締約方

• 分子診斷領域最活躍的締約方
• 分子診斷領域最活躍的簽約方的公司簡介

第5章 分子診斷合約目錄

• 分子診斷合約目錄

第6章 分子診斷合約：依技術類型分類

• 合約目錄
• 合約目錄：按公司名稱（A-Z）排列的分子診斷合約
• 合約目錄：按合約類型分類的分子診斷合約
• 合約目錄：按治療領域分類的分子診斷合約
• 合約類型的定義
• 關於 Biopharma Research Ltd.
• 關於當前合作夥伴關係
• 關於現行協議
• Current Partnering 最新報告列表

The definitive benchmark for molecular diagnostics dealmaking

Molecular diagnostics partnering is driven by advanced genomic and biomarker-based testing technologies, with deal structures reflecting the growing role of precision diagnostics in clinical decision-making and therapeutic development.

This report provides a comprehensive and structured analysis of 830+ molecular diagnostics collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how molecular diagnostics deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by technology platform, testing application, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a precision-driven and clinically integrated landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within molecular diagnostics partnerships, particularly where regulatory requirements, clinical utility, and testing accuracy are key considerations.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark diagnostic and precision medicine transactions
• Prepare for negotiations with well-defined market context
• Evaluate technology partners and collaboration opportunities
• Support internal strategy with robust, defensible data
• What's included
• 830+ molecular diagnostics collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, technology, and application)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for molecular diagnostics dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how molecular diagnostics partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

• 2.1. Introduction
• 2.2. Molecular diagnostics deals over the years
• 2.3. Most active molecular diagnostics dealmakers
• 2.4. Molecular diagnostics deals by deal type
• 2.5. Molecular diagnostics deals by therapy area
• 2.6. Molecular diagnostics deals by industry sector
• 2.7. Deal terms for molecular diagnostics deals
  • 2.7.1 Molecular diagnostics deals headline values
  • 2.7.2 Molecular diagnostics deal upfront payments
  • 2.7.3 Molecular diagnostics deal milestone payments
  • 2.7.4 Molecular diagnostics royalty rates

Chapter 3 - Leading molecular diagnostics deals

• 3.1. Introduction
• 3.2. Top molecular diagnostics deals by value

Chapter 4 - Most active molecular diagnostics dealmakers

• 4.1. Introduction
• 4.2. Most active molecular diagnostics dealmakers
• 4.3. Most active molecular diagnostics deals company profiles

Chapter 5 - Molecular diagnostics contracts dealmaking directory

• 5.1. Introduction
• 5.2. Molecular diagnostics contracts dealmaking directory

Chapter 6 - Molecular diagnostics dealmaking by technology type

• Deal directory
• Deal directory - Molecular diagnostics deals by company A-Z
• Deal directory - Molecular diagnostics deals by deal type
• Deal directory - Molecular diagnostics deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Molecular diagnostics deals since 2016
• Figure 2: Active molecular diagnostics dealmaking activity since 2016
• Figure 3: Molecular diagnostics deals by deal type since 2016
• Figure 4: Molecular diagnostics deals by therapy area since 2016
• Figure 5: Molecular diagnostics deals by industry sector since 2016
• Figure 6: Molecular diagnostics deals with a headline value
• Figure 7: Molecular diagnostics deals with an upfront value
• Figure 8: Molecular diagnostics deals with a milestone value
• Figure 9: Molecular diagnostics deals with a royalty rate value
• Figure 10: Top molecular diagnostics deals by value since 2016
• Figure 11: Most active molecular diagnostics dealmakers since 2016
• Figure 12: Molecular diagnostics deals by technology type since 2016